Feed/Companies/Nouscom

Nouscom

As of 28 Oct 2026, Nouscom has raised $133.8M across 1 verified round on record (amounts in other currencies converted to USD), plus 3 rounds still being checked; latest: €120 million ($135 million) Series D led by M Ventures and Revelation Partners, announced 19 Oct 2026.

BUILT ON

Nouscom is a biotech company selling cancer-preventing vaccine candidates primarily to healthcare providers and clinical trial organizations.

intesasanpaolo.comLinkedInBasel, SwitzerlandBiotechFounded 201559 employees as of Sep 30, 2026

LATEST ROUND

Series D

$133.8M · 2026-10-19

RAISED ON RECORD · USD

$133.8M

across 1 verified round · plus 3 rounds still being checked

INVESTORS

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Rounds

[ 4 ]

Series D

$133.8M · 2026-10-19

led by M Ventures, Revelation Partners

Series C

$72.4M · 2023-11-14

[ HISTORY ]

led by Andera Partners, Bpifrance, M Ventures

Series B

$48.7M · 2017-11-06

[ HISTORY ]

lead not stated

Series A

$13.6M · 2016-05-17

[ HISTORY ]

led by Life Sciences Partners, Versant Ventures

Round	Amount	Announced	Lead	Buzz
Series D	$133.8M €120 million ($135 million)	2026-10-19	M Ventures, Revelation Partners	No recent discussion
7 sources · checked 1 time, last 2h ago [ VERIFIED · CORRECTED ] read against 4 of 7 sources Removed European Investment Bank (EIB) · no source places them in this round Source 1 also gives the equivalent as $135 million; the more specific financing accounts' €120 million is used. Sources differ on whether Angelini Ventures was new or existing; it is included because Source 2 says it participated.

Company research

Fetched today

Nouscom develops engineered viral-vector cancer vaccines and immunotherapies for people with cancer and people at high inherited risk of cancer.

Founders

Riccardo Cortese · Co-Founder
He founded Okairos, an infectious-disease genetic-vaccine company, and led it through its successful acquisition by GSK in 2013.
Cinzia Traboni · Co-Founder and R&D GMO Manager
Before Nouscom, she spent 17 years at the Merck laboratory in Rome (IRBM), mainly as a group leader working on antivirals against hepatitis C virus.
Elisa Scarselli · Chief Scientific Officer and Co-Founder
Before joining Okairos, she was a scientist at IRBM/Merck from 1992 and then a group leader in oncology, and she also carried out malaria research at ZMBH in Heidelberg.

Total raised

$287M · as its sources put it, more than the rounds on record

WHY IT MATTERS

Nouscom is pursuing an off-the-shelf vaccine, NOUS-209, that delivers 209 shared frameshift neoantigens to train the immune system to attack precancerous and cancerous cells in Lynch syndrome, where current management is largely surveillance and surgery and lifetime cancer risk can reach 80%. The €120 million Series D will fund a global registration-enabling trial, after Phase 1b/2 data reported all evaluable vaccinated carriers free of advanced adenomas and colorectal cancer at years 1 and 2, while annual retreatment strengthened T-cell responses.

Nouscom

Company

Rounds

Sources

Profile

Investors

Nouscom

Rounds

Company research

Sources

Series D$133.8M2026-10-197 sources

Series C$72.4M2023-11-141 source

Series B$48.7M2017-11-062 sources

Series A$13.6M2016-05-171 source

Investors

Series D$133.8M2026-10-1913 investors

Series C$72.4M2023-11-147 investors

Series A$13.6M2016-05-172 investors

Series C [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$72.4M €67.5 million ($72 million)	2023-11-14	Andera Partners, Bpifrance, M Ventures	No recent discussion
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source Removed 5AM Ventures, EQT Life Sciences, Versant Ventures · not in this round The release distinguishes the round participants from continued support by existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures; those existing investors are not counted in this round. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: anderapartners.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$48.7M €42 million	2017-11-06	not stated	No recent discussion
2 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 2 sources [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]2 pages read: wsj.com, versantventures.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 1 of 2 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent

Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$13.6M €12 million ($13.6 million)	2016-05-17	Life Sciences Partners, Versant Ventures	No recent discussion
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source Leads added Life Sciences Partners, Versant Ventures · wsj.com The source says Nouscom is Swiss but does not provide a headquarters city. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: wsj.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 1 source·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent